LYONS GARY A 4

What Happened

• Gary A. Lyons, a director of Neurocrine Biosciences, was granted two awards totaling 3,908 restricted stock units (RSUs) on May 27, 2026 (1,284 RSUs and 2,624 RSUs). The filing shows an acquisition price of $0.00, indicating these are compensation awards rather than cash purchases or sales.

Key Details

• Transaction date: 2026-05-27; Form 4 filed: 2026-05-29 (filed within two business days).
• Transaction type/code: Award/Grant (A); reported as derivative securities (RSUs).
• Share counts/prices: 1,284 RSUs @ $0.00 and 2,624 RSUs @ $0.00 — total 3,908 RSUs.
• Vesting: Per footnote, each RSU converts to one share upon vesting; all RSUs vest in full on May 27, 2027 (F1, F2).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Additional footnote (F3): references an option vesting schedule beginning June 27, 2026; no option exercise transaction is reported in this filing.
• Filing timeliness: Reported promptly (filed two days after the grant).

Context

• RSUs are a form of equity compensation that convert into common shares when they vest; no cash was paid at grant and no shares were immediately issued or sold. Such grants are typically part of director compensation and do not by themselves indicate buying or selling sentiment.